How to cover Novartis’ $475K CAR-T drug Kymriah? A ‘new payment model’ is the only way, Express Scripts says
admin 22nd September 2017 Uncategorised 0Steve Miller, the chief medical officer of Express Scripts, is one of the loudest voices in the ongoing debate over high drug prices, so it was only a matter of time before he weighed in on Kymriah, Novartis’ $475,000 CAR-T treatment for some patients with leukemia. That time came yesterday, and Miller didn’t mince words in his assessment of the new product’s price.
More: How to cover Novartis’ 5K CAR-T drug Kymriah? A ‘new payment model’ is the only way, Express Scripts says
Source: fierce